• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training

    9/30/24 7:35:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email
    • Accuray is the first industry partner to open a facility at the Genolier Innovation Hub, created to provide opportunities for clinician-industry collaborations that can help accelerate improvements in patient care
    • New Accuray CyberComm™ tool was used to significantly reduce the CyberKnife® S7™ System's commissioning time and enable product training in Genolier to begin more quickly

    MADISON, Wis., Sept. 30, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the initiation of CyberKnife® S7™ System medical professional training at its education center located within the newly opened Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA, in Switzerland. As the first industry partner to have a presence at the hub, Accuray now offers product training, and facilitates sharing of best practices and innovative techniques, on both its CyberKnife and Radixact® Radiation Treatment Delivery Systems. Accuray began hosting Radixact System educational courses earlier in 2024.

    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

    A three-day series of events marked the grand opening of the state-of-the-art Genolier Innovation Hub, unique in Europe. "We congratulate the Genolier Innovation Hub team on the launch of their new facility and network. They are changing the model for cross-disciplinary collaboration in support of advancing patient care," said Sandeep Chalke, interim CEO & Senior Vice President, Chief Commercial Officer, at Accuray.

    Continued Mr. Chalke, "We opened our European education center within the hub to expand access to advanced training to more Accuray CyberKnife and Radixact System users. We are committed to improving the lives of people diagnosed with cancer and this goal is intricately linked to our customers' ability to optimize their use of our systems. The opportunity to easily access training, such as the courses we offer at our center in Genolier, is critical to their success."

    The Accuray education center in Genolier was designed from the ground up to provide a comprehensive learning experience. The training curriculum is created to reflect the distinctive needs of the diverse medical professionals involved in the care of patients treated using radiosurgery and radiotherapy. Course attendees have access to expert instructors and hands-on simulation facilities for training and demonstrations of the CyberKnife and Radixact Systems.

    The CyberKnife and Radixact Systems have complementary clinical applications with the same goal: to empower customers to deliver the most precise and accurate treatments while still minimizing dose to healthy tissue, helping to reduce the risk of side effects that may impact patients' quality of life. The systems include advanced functionality that make it easier and more efficient to administer extremely precise radiation treatments, even to targets that move, providing the medical care team with options for managing the full spectrum of cancer cases, from routine to complex and initial treatment to retreatment, and neurologic disorders.

    About Accuray

    Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

    Safe Harbor Statement

    Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations related to expectations regarding the Genolier Innovation Hub and the Company's education center located within Genolier; expectations regarding the Company's training curriculum; and expectations regarding the Company's products. These risks and uncertainties include, but are not limited to, the effect of the current global economic environment, including in connection to the COVID-19 pandemic, on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; reliance on third party collaborators, partnerships, strategic alliances and joint ventures; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on September 19, 2024, and as updated periodically with the company's other filings with the SEC.

    Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

    Media Contact

    Beth Kaplan

    Public Relations Director, Accuray

    +1 (408) 789-4426

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-celebrates-opening-of-genolier-innovation-hub-in-switzerland-initiation-of-cyberknife-s7-system-medical-professional-training-302262088.html

    SOURCE Accuray Incorporated

    Get the next $ARAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Accuray Incorporated

    SCHEDULE 13D/A - ACCURAY INC (0001138723) (Subject)

    4/17/26 6:03:17 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ACCURAY INC (0001138723) (Filer)

    4/7/26 9:00:20 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ACCURAY INC (0001138723) (Filer)

    4/6/26 9:00:13 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Accuray with a new price target

    ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

    2/13/24 6:29:42 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on Accuray with a new price target

    B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

    6/23/22 7:25:39 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Loop Capital initiated coverage on Accuray with a new price target

    Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

    12/22/21 4:56:14 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

    MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transform

    4/6/26 9:00:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Reports Fiscal 2026 Second Quarter Financial Results

    MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights  On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and organizational transformational plan, which is expected to improve annualized operating profitability by approximately $25 million and set the stage for revenue growth:Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competi

    2/4/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026

    MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 4, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (interna

    1/21/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/20/26 4:10:06 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    CEO La Neve Stephen R. bought $19,410 worth of shares (20,000 units at $0.97) (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    11/19/25 5:18:33 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Tcw Group Inc

    3 - ACCURAY INC (0001138723) (Issuer)

    4/17/26 6:01:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Miele Paul Michael

    3 - ACCURAY INC (0001138723) (Issuer)

    4/10/26 4:40:03 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chalke Sandeep

    4 - ACCURAY INC (0001138723) (Issuer)

    4/1/26 5:14:50 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Leadership Updates

    Live Leadership Updates

    View All

    Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

    MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transform

    4/6/26 9:00:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth

    Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEOCompany Appoints Steven F. Mayer as Transformation Board SponsorChan W. Galbato Nominated to Board of Directors MADISON, Wis., Oct. 20, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this work, the company's Board of Directors has appointed proven industry leaders with deep operational expertise to drive execution, strengthen performance, and enhance competitiveness. The transformation plan initiatives, most of which will be implemented during the current fisc

    10/20/25 9:20:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ARAY
    Financials

    Live finance-specific insights

    View All

    Accuray Reports Fiscal 2026 Second Quarter Financial Results

    MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights  On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and organizational transformational plan, which is expected to improve annualized operating profitability by approximately $25 million and set the stage for revenue growth:Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competi

    2/4/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026

    MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 4, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (interna

    1/21/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Reports Fiscal 2026 First Quarter Financial Results

    MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the first quarter ended September 30, 2025. Key Highlights  On October 20, 2025, the Company announced accelerated transformation efforts, including:Appointed Steve La Neve as President and Chief Executive Officer. He succeeds Suzanne Winter, who will retire after six years of service and remain in an advisory role through the end of November 2025.Appointed Steven F. Mayer, a member of the Board of Directors, as the Transformation Board Sponsor to lead the Compan

    11/5/25 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    9/6/24 9:00:07 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Accuray Incorporated

    SC 13G - ACCURAY INC (0001138723) (Subject)

    2/13/24 4:56:01 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    2/13/24 11:19:22 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care